Anaptysbio (ANAB) Operating Leases (2021 - 2026)
Anaptysbio's (ANAB) quarterly Operating Leases came in at $11.5 million in Q1 2026, down 15.57% YoY from $13.6 million in Q1 2025, and down 4.48% on a QoQ basis from $12.0 million in Q4 2025.
Anaptysbio (ANAB) Operating Leases (2021 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 6 years of Operating Leases data on file, last reported at $11.5 million in Q1 2026.
- Quarterly Operating Leases fell 15.57% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 15.57% YoY) and the FY2025 annual result came in at $12.0 million, down 14.74% from the prior year.
- Operating Leases fell to $11.5 million in Q1 2026, from $12.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $20.2 million in Q2 2022 to a low of $11.5 million in Q1 2026.
- A 5-year average of $15.8 million and a median of $16.0 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases dropped 2.67% — and 2025, when it declined 22.73%.
- Tracing ANAB's Operating Leases over 5 years: stood at $17.8 million in 2022, then retreated by 9.97% to $16.0 million in 2023, then retreated by 12.0% to $14.1 million in 2024, then decreased by 14.74% to $12.0 million in 2025, then declined by 4.48% to $11.5 million in 2026.
- The last three Operating Leases figures came in at $11.5 million (Q1 2026), $12.0 million (Q4 2025), and $12.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.49 Mn |
| Dec 31, 2025 | 12.03 Mn |
| Sep 30, 2025 | 12.57 Mn |
| Jun 30, 2025 | 13.10 Mn |
| Mar 31, 2025 | 13.61 Mn |
| Dec 31, 2024 | 14.11 Mn |
| Sep 30, 2024 | 14.61 Mn |
| Jun 30, 2024 | 16.95 Mn |
| Mar 31, 2024 | 15.58 Mn |
| Dec 31, 2023 | 16.04 Mn |
| Sep 30, 2023 | 16.49 Mn |
| Jun 30, 2023 | 18.65 Mn |
| Mar 31, 2023 | 17.39 Mn |
| Dec 31, 2022 | 17.81 Mn |
| Sep 30, 2022 | 18.24 Mn |
| Jun 30, 2022 | 20.22 Mn |
| Mar 31, 2022 | 19.06 Mn |
| Dec 31, 2021 | 19.45 Mn |
| Sep 30, 2021 | 19.84 Mn |
| Jun 30, 2021 | 20.78 Mn |